It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Cry11Aa and Cry11Ba are the two most potent toxins produced by mosquitocidal Bacillus thuringiensis subsp. israelensis and jegathesan, respectively. The toxins naturally crystallize within the host; however, the crystals are too small for structure determination at synchrotron sources. Therefore, we applied serial femtosecond crystallography at X-ray free electron lasers to in vivo-grown nanocrystals of these toxins. The structure of Cry11Aa was determined de novo using the single-wavelength anomalous dispersion method, which in turn enabled the determination of the Cry11Ba structure by molecular replacement. The two structures reveal a new pattern for in vivo crystallization of Cry toxins, whereby each of their three domains packs with a symmetrically identical domain, and a cleavable crystal packing motif is located within the protoxin rather than at the termini. The diversity of in vivo crystallization patterns suggests explanations for their varied levels of toxicity and rational approaches to improve these toxins for mosquito control.
An environmentally safe means of mosquito control is the application of Bacillus thuringiensis israelensis, which produces a cocktail of four naturally crystalline proteins exclusively toxic to mosquito. Here the authors report the atomic-resolution structures of Bti Cry11Aa and related Btj Cry11Ba solved de novo through Serial Femtosecond Crystallography on naturally-occurring nanocrystals.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
































1 Univ. Grenoble Alpes, CNRS, CEA, Institut de Biologie Structurale, Grenoble, France (GRID:grid.4444.0) (ISNI:0000 0001 2112 9282)
2 University of California, UCLA-DOE Institute for Genomics and Proteomics, Department of Biological Chemistry, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718)
3 Univ. Grenoble Alpes, CNRS, CEA, Institut de Biologie Structurale, Grenoble, France (GRID:grid.4444.0) (ISNI:0000 0001 2112 9282); Max-Planck-Institut für medizinische Forschung, Heidelberg, Germany (GRID:grid.414703.5) (ISNI:0000 0001 2202 0959)
4 University of California, UCLA-DOE Institute for Genomics and Proteomics, Department of Biological Chemistry, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718); University of California, Department of Chemistry and Biochemistry, Los Angeles, USA (GRID:grid.19006.3e) (ISNI:0000 0000 9632 6718)
5 Institut Laue-Langevin, Large-Scale Structures Group, Grenoble, France (GRID:grid.156520.5) (ISNI:0000 0004 0647 2236)
6 Lawrence Berkeley National Laboratory, Molecular Biophysics and Integrated Bioimaging Division, Berkeley, USA (GRID:grid.184769.5) (ISNI:0000 0001 2231 4551)
7 Max-Planck-Institut für medizinische Forschung, Heidelberg, Germany (GRID:grid.414703.5) (ISNI:0000 0001 2202 0959)
8 SLAC National Accelerator Laboratory, Linac Coherent Light Source, Menlo Park, USA (GRID:grid.445003.6) (ISNI:0000 0001 0725 7771)
9 Max-Planck-Institut für medizinische Forschung, Heidelberg, Germany (GRID:grid.414703.5) (ISNI:0000 0001 2202 0959); European XFEL GmbH, Schenefeld, Germany (GRID:grid.434729.f) (ISNI:0000 0004 0590 2900)
10 Texas A&M University, Department of Chemistry, College Station, USA (GRID:grid.264756.4) (ISNI:0000 0004 4687 2082)
11 University of California, Department of Entomology and Institute for Integrative Genome Biology, Riverside, USA (GRID:grid.266097.c) (ISNI:0000 0001 2222 1582); California Baptist University, Department of Biological Sciences, Riverside, USA (GRID:grid.411853.a) (ISNI:0000 0004 0459 0896)
12 European XFEL GmbH, Schenefeld, Germany (GRID:grid.434729.f) (ISNI:0000 0004 0590 2900)
13 European Synchrotron Radiation Facility (ESRF), BP 220, Grenoble, France (GRID:grid.5398.7) (ISNI:0000 0004 0641 6373)
14 University of Southern California, Mass Spectrometry Core Facility, School of Pharmacy, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853)
15 University of Southern California, Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, Los Angeles, USA (GRID:grid.42505.36) (ISNI:0000 0001 2156 6853)
16 Univ. Grenoble Alpes, CNRS, LECA, Grenoble, France (GRID:grid.462909.0) (ISNI:0000 0004 0609 8934)
17 Université Claude Bernard Lyon 1, Laboratoire de Chimie, Univ. Lyon, ENS de Lyon, CNRS UMR 5182, Lyon, France (GRID:grid.463879.7) (ISNI:0000 0004 0383 1432)
18 Polyvalan SARL, Lyon, France (GRID:grid.463879.7)
19 University of California, Department of Entomology and Institute for Integrative Genome Biology, Riverside, USA (GRID:grid.266097.c) (ISNI:0000 0001 2222 1582)